Scopus
YÖKSİS Eşleşti
The use of buprenorphine + naloxone sublingual tablet in the treatment of neonatal opioid withdrawal syndrome: Two case reports
Journal of Addictive Diseases · Ocak 2022
YÖKSİS Kayıtları
The use of buprenorphine + naloxone sublingual tablet in the treatment of neonatal opioid withdrawal syndrome: Two case reports
Journal of Addictive Diseases · 2022 SSCI
DOÇENT ALİ KANDEĞER →
Makale Bilgileri
DergiJournal of Addictive Diseases
Yayın TarihiOcak 2022
Cilt / Sayfa40 · 432-438
Scopus ID2-s2.0-85120751795
Özet
Introduction: Neonatal opioid withdrawal syndrome occurs after exposure during pregnancies of mothers with an opioid use disorder. If non-pharmacological treatment is insufficient, pharmacological options are preferred, but a common treatment guideline has not yet been determined. Sublingual buprenorphine tablet is more prominent in the treatment. Since oral alternatives are not available in many clinics, as in our unit, parenteral morphine is still the drug of the first choice. In this paper, we reported that two babies with neonatal opioid withdrawal syndrome were successfully treated with a buprenorphine/naloxone combination, which was not previously shown in the literature. Cases: We followed two babies whose mothers had an opioid use disorder during their pregnancies. The modified Finnegan scoring scale was used for the assessment of the babies. Both infants developed persistent seizures with resistant withdrawal signs. An effective parenteral route could not be provided due to hemodynamic instability. Thus, IV morphine could not be used. Due to the lack of oral treatment alternatives, first, we tried phenobarbital up to 40 mg/kg orally. Afterward, we used buprenorphine/naloxone combined tablet sublingually, which has not been used in children before. Detailed written consent was obtained from the parents for the emergency use of this drug in advance. Shortly after this treatment, the seizures and withdrawal signs were controlled. There were no adverse effects and babies were discharged fully recovered. Conclusion: Sublingual Buprenorphine 2 mg + Naloxone 0.5 mg (4:1) tablet could be used efficiently and without side effects to treat neonatal opioid withdrawal syndrome.
Yazarlar (3)
1
Ersin Ulu
ORCID: 0000-0002-9798-2367
2
Ali Kandeger
ORCID: 0000-0001-6940-0940
3
Rüya Meriç
ORCID: 0000-0002-9899-7050
Anahtar Kelimeler
Buprenorphine/Naloxone
case report
eat sleep console
neonatal opioid withdrawal syndrome
newborn
Kurumlar
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty of Medicine
Istanbul Turkey
Selçuk Tip Fakültesi
Konya Turkey